2019 China's top 500 listed companies ranked 12 health care companies shortlisted.

As of May 1,
the 2019 financial results of Chinese mainland, Hong Kong, and U.S. listed companies were largely disclosed, and the list of top 500 listed companies in China was released (according to Oriental Wealth Choice data, according to 2019 corporate operating income).
Oriental Wealth Choice data show: 1) The threshold for China's top 500 listed companies in 2019 is 19 billion yuan, up from 17.6 billion yuan the previous year, and 2) the total revenue of China's top 500 listed companies in 2019 reached 52.1 trillion yuan, accounting for nearly 80% of the total revenue of listed companies.
according to GICS (Global Industry Classification Standard), 2019 China's top 500 listed companies cover industry, raw materials, non-daily consumer goods, real estate, information technology, finance, consumer goods, utilities, energy, healthcare, communications services, of which the healthcare industry entered the top 500 enterprises a total of 12. In volume, the same amount as in 2018, total revenue increased by 0.17 trillion yuan compared to 2018 (2018 China's top 500 listed companies in health care total revenue of 0.89 trillion yuan), but revenue accounted for a decrease compared to 2018.
the 12 pharmaceutical and health care companies that are shortlisted in the top 500 listed companies in China in 2019 have half of their revenues of about 20 billion yuan, their China Pharmaceutical Holdings, Shanghai Pharma and China Resources Pharmaceuticals revenue of more than 180 billion yuan, and Baiyun's revenue of 65 billion yuan, the author will analyze the 12 pharmaceutical and health care companies and their performance.. China Pharmaceutical Sinabe, China's pharmaceutical, healthcare products wholesalers, retailers and supply chain service providers, in 2019 the main project of the "troika" - drugs, retail, equipment co-development, achieved full-year revenue of 425,272.73 million yuan, up 23.44 percent year-on-year. Among them, distribution business revenue reached RMB337.317 billion, up 20.02% YoY, retail revenue was RMB19.803 billion, up 33.77% YoY, and medical device business revenue was RMB69.293 billion, up 40.06% YoY.
pharmaceutical distribution, With the integrated pharmaceutical supply chain and advanced supply chain management model, Guopharma Holdings further promotes the sinking of the distribution network, strengthens the coverage and service capacity of medical terminals such as second- and third-tier hospitals, private hospitals, community medical treatment, township hospitals, and acquires Anhui Province (Pharmaceuticals) Group Co., Ltd. and Guizhou Yitong Pharmaceutical Co., Ltd. (70% equity) in 2019. Retail business, under the guidance of the strategy of "zero integration", actively improve the provincial platform construction, implement a unified standardized construction and chain certification system, promote the overall upgrading of retail brands, in addition to making full use of the advantages of the distribution supply chain system and the accumulation of hospital customer resources, build a professional pharmacy system, as of 2 On December 31, 019, the company's national pharmacy stores cover 19 provinces, municipalities and autonomous regions, with 5,021 retail pharmacies, professional pharmacy stores reached 1183, covering 30 provinces, municipalities and autonomous regions. Medical devices, in 2019 to vigorously promote business integration, strengthen resource docking, deepen strategic cooperation between upstream and downstream enterprises, explore professional integrated services programs, promote medical supplies supply chain management.
Shanghai Pharma is a large pharmaceutical industry group listed in Shanghai and Hong Kong, its main business covers the pharmaceutical industry, distribution and retail, and in 2019 achieved operating income of 186.566 billion yuan, up 17.27 percent year-on-year, with the pharmaceutical industry achieving revenue of 23.49 billion yuan, up 20.7 percent year-on-year, and the pharmaceutical industry' revenue of 26.7 billion yuan.
the pharmaceutical industry, Shanghai Pharma will have 35 varieties in 2019, an increase of 4 from 2018. In addition, the company in overseas markets approved api and preparation varieties are further expanded. In research and development, the company's total investment in research and development in 2019 was RMB 1,509 million, with cost-based investment of RMB1.350 billion, up 27.22% YoY. Of these, 34.13% of the cost of independent research and development was invested in innovative drug research and development, and made more stage progress, such as SPH3127 completed the clinical phase II of all patients into the group, and started two new indications exploration research; In addition, the company has a total of 5 varieties in 2019 through consistency evaluation.
pharmaceutical business, Shanghai Pharma through the acquisition of Sichuan Guojia, enhance its influence in the southwest region, and complete the jiangsu, Heilongjiang, Jilin and other provinces of the provincial platform construction and network extension layout, further improve the national layout. At the same time, the integration of Condele and Liaoning's foreign trade has been steadily advanced, successfully achieving the established goal of exerting the scale effect and rapidly improving profitability. In addition, Shanghai Pharmaceuticals has given full play to its advantages in importing services, and has achieved strategic cooperation with many multinational enterprises, and has made great efforts to achieve accelerated development under the impetus of heavy new drugs. It is reported that in 2019 the company has acquired 17 new imports of new drugs of the national general agent, including dacotini tablets, cephalosporine avibatan sodium, Peliju monotonica, Peselizumab, Alisi Uspen, Nzaluamine and other heavyweight varieties.
new business area, the company's vaccine import business in 2019 continued to maintain its advantages and high growth trend, providing supply chain extension (SPD) services to 248 hospitals nationwide, and providing lean logistics management services in the entire supply chain closed loop according to the individual needs of each hospital. In addition, the online business with the electronic prescription platform as the core is booming, with more than 10 million electronic prescriptions flowing throughout the year, nearly 200,000 patients in the cumulative service of innovative financial services, and the operation of Zhenjiang Internet Hospital is also on track.
China Resources Pharmaceuticals is a comprehensive pharmaceutical company in China, covering the production, distribution and retailing of pharmaceutical and health care products. In 2019, China Resources Pharmaceuticals achieved total revenue of HK$204.45 billion, hkD 7.78 billion in Hong Kong dollar calculations, profit of HK$5,098 million, a negative growth of 32.68 percent YoY, while the company's negative growth mainly came from its Dong'a gu, it is understood that in 2019 Shandong Agu's revenue of 2,959 million, a decrease of 59.68 percent YoY, a net profit loss of 444 million.
China Resources Pharmaceuticals is a state-controlled, pharmaceutical, China Resources three major commercial giants in the pharmaceutical sector large commercial companies, one of the focus of its manufacturing industry is over-the-counter drugs, its 39, Dong a gu, Jiangzhong, Tianand, Wei and other well-known brands, it is understood that 2019 with over-the-counter drugs as the core including nutritional health food, "self-diagnosis" business sector income reached HK$13.264 billion.
2019, the company's pharmaceutical industry revenue was HK$33.806 billion, a negative growth of 3.53% YoY, while the pharmaceutical business sector's revenue was RMB13.7 billion, up 50% YoY. As of 2019, China Resources Pharmaceutical Commercial Distribution Network covers 28 provinces, municipalities and autonomous regions, with customers including about 7,000 hospitals at levels 2 and 3, more than 47,000 primary medical institutions and nearly 55,000 retail pharmacies.
in addition, in addition, in 2019 the company around the "reform and innovation, quality development" strategic general approach to promote the strategic landing, biological drug layout breakthrough, through the implementation of a number of international business cooperation projects and high-quality mergers and acquisitions projects to accelerate the integration of upstream products and downstream channel resources, accelerate the cultivation of high-potential business, and vigorously promote the integrated layout.
2019, Baiyunshan's operating income was RMB64,952 million, up 53.79 percent year-on-year, but net profit attributable to shareholders of the company was RMB3,189 million, down 7.33 percent year-on-year. Among them, the company's two major star products are still performing better, to Wang Laoji herbal tea as the core product selling Wang Laoji big health company's main business income of 10.297 billion yuan, domestic "Viagra" - siddy sidingin ("Golden Go") gross margin increased by 3.29 percentage points, single-item revenue of 753 million yuan.
Baiyunshan business is divided into "Danan Medicine", "Big Health", "Big Business", "Big Medical" four major sectors, of which "Great Southern Medicine" and "Big Business" sector gross margin decreased by 4.89 percentage points and 0.22 percentage points, respectively, while the "Big Health" sector increased by 7.38 percentage points to a record high of 50.81%. It is worth mentioning that of the 18 main products in the Dae-Southern pharmaceutical business, only 5 products have a positive gross margin growth.
2019, the company's research and development costs of 577 million yuan, down 1.53% from 2018, in sharp contrast to sales costs of 6.385 billion yuan, up 26.26% YoY, one of the most important growth is the growth of advertising costs.
East China Medicine is mainly engaged in the production and sale of antibiotics, traditional Chinese medicine, chemical synthetic drugs, genetic engineering drugs, as well as Chinese and Western medicine, Chinese medicine, medical equipment and other batch zero distribution business, is a pharmaceutical research and development, pharmaceutical industry, pharmaceutical distribution, retail, pharmaceutical logistics as one of the large-scale integrated pharmaceutical listed company. In 2019, the company's revenue was RMB35.446 billion, up 15.60% YoY, with sales of the pharmaceutical industry exceeding RMB10 billion for the first time, achieving a historic leap.
with the continuous deepening and promotion of the volume of procurement, the profits of generic drugs are constantly compressed, the company began to promote the transformation of research and development in all directions, through independent research and development and cooperation commissioned development and product authorization combined with the new drug research and development model layout, accelerate enterprise innovation, rapid strengthening of the strength of the research and development team, research and development personnel from 550 rapidly expanded to 1078.
2019 investment in research and development of the pharmaceutical industry was RMB 1,055 million, up 49.14% YoY, and built a global research and development strategic collaborative ecosystem centered on East China, perfected the research and development project approval and dynamic evaluation system; In addition, the company has entered into strategic cooperation with R2, MediBeacon and Kylane of Switzerland, access to a number of innovative products of international commercialization rights, further enrichthe the product pipeline, add momentum to development.
Yunnan White Medicine is a century-old Chinese brand founded in 1902, well-known trademarks in China, among the first national innovative enterprises, revenue of 29.665 billion yuan in 2019, up 9.80% year-on-year. Among them, the provincial pharmaceutical sector revenue of 19.01 billion yuan (YoY. 16.41%), pharmaceutical wholesale, retail business steady and good, health sector revenue of 4.67 billion (YoY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . With an annual production capacity of 500 million units), the first unattended toothpaste trial production marks the arrival of the era of intelligent industry 4.0, and the revenue of the Chinese medicine resources sector is 1.368 billion (YoY , 0.04%), and the new retail model led by "White Medicine Life and Experience Store" (continuously strengthening sales from the front end of the industrial chain to the back end, such as the "Panther 737" brand).
it is worth mentioning that in 2019 the company successfully completed the second phase of the mixed ownership reform and reverse absorption merger of controlling shareholder Yunnan White Pharmaceutical Holdings Co., Ltd.
Fosun Pharma is China's medical and health industry group, covering the entire pharmaceutical and health industry chain, including pharmaceutical manufacturing and research and development, medical services, medical devices and medical diagnostics, pharmaceutical distribution and retail, which focus on pharmaceutical manufacturing and research and development, and medical services as the focus of development. Fosun Pharma achieved operating income of RMB28,585 million in 2019, an increase of 14.72% over 2018.
core business of pharmaceutical manufacturing and research and development, in 2019 achieved operating income of 21.766 billion yuan, an increase of 16.51% over 2018. In 2019, the company's sales of more than 100 million yuan of preparation products increased to 35, of which more than 500 million varieties reached 10. It is worth mentioning that its litoxim-synofre injection (Hanlikang) as China's first independently developed biosimilar drug market, the core products non-bustathasia tablets (Ulysses), pivastatin calcium tablets (Bang) and Enoxin sodium injection sales increased significantly, 105%, 113% and 57%, respectively.
medical device sander and medical diagnostics business, through endogenous operations and extended mergers and acquisitions, achieved operating income of RMB3.736 billion in 2019, an increase of 2.66 percent over 2018. Among them, the joint venture intuitive Fosun "Da Vinci Surgical Robot" as the world's only current fda and the National Drug Administration licensed to market the minimally invasive cavity mirror surgical robot products, installed capacity and surgical volume are rapid growth, installed in 2019 reached 60 units, in Chinese mainland and Hong Kong surgery volume of more than 40,000. In addition, sales of HPV diagnostic reagents and thalassemia genetic testing reagents have grown rapidly.
health care services, revenue was RMB3,040 million in 2019, up 18.61 percent from 2018. At present, the Pearl River Delta Great Bay Area, Yangtze River Delta, Huaihai Economic Zone as the key areas of medical services, specialty and general hospitals combined strategic layout. By the end of 2019, the total number of beds approved by more than 10 medical service institutions controlled by Fosun Pharmaceutical Group was 4,328. In addition, Fosun Pharma is actively exploring new Internet-based medical services and products.
in innovation and research, Fosun Pharma continued to improve the "imitation combination" of drug research and development system in 2019, and continuously increased investment, with research and development investment in 2019 reaching 3.463 billion yuan, up 38.15 percent year-on-year, of which the pharmaceutical business investment was 3.131 billion yuan, an increase of 39.12 percent. In 2019, the company will focus on increasing investment in research and development of small molecule innovation drugs, monoclonal antibody bio-innovation drugs and biosimilars, CAR-T cell drugs, and systematically promote the introduction and registration of drug licenses and the evaluation of generic consistency.
, Fosun Pharma has continued to promote its internationalization strategy, with overseas revenues reaching RMB6.622 billion, up 12.12% from 2018. It is reported that a total of 15 generic products were approved by the FDA during the reporting period. To enrich its product line, in partnership with ReNeuron, a global cell therapy company, has introduced cell therapy products for post-stroke disability and retinal pigmentation, and has been licensed by MimiVax to exclusively develop and commercialize glioblastoma immunotherapy products. SurVaxM.
China Biopharmaceutical sourcing is a comprehensive and group pharmaceutical company, mainly through the application of advanced biotechnology and China.